Stoneflyadds new SVP, client advisor

Share this article:
Stonefly Communications Group has named R. Steven Lang as senior vice president/client advisor. Lang will be providing strategic marketing counsel and guidance to the brand teams of several key healthcare clients, as well as leading the agency teams responsible for implementing cross-channel communication campaigns.
Lang co-founded DVC HealthCare, a communications company specializing in the commercialization of new products.
"Steve brings an ideal mix of experiences to the client advisor role," said John Racik, chief executive of Stonefly. "As a former client-side pharmaceutical marketer, he has deep therapeutic expertise and unparalleled knowledge of the commercialization process. Having also served on the professional services side, he understands how to integrate both left brain and right brain thinking to create campaigns that move business. He will be a strong asset to our teams and our clients' business."
"Stonefly's client advisor (CA) model is unique," said Racik. "By placing seasoned marketers, like Steve, on site with clients, we can ensure that our customers always have access to senior-level experts who can work as an integrated part of their marketing team. In addition, clients can provide mentorship to less experienced members of the client's brand team. It also enhances the agency's ability to produce work that is strategically on-target."
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.